- This cancer stock doubles the survival rate with little to no downside compared to other cancer treatments.
- What’s more? This gem has just been green-lit for insurance reimbursement approval for 84 German hospitals, making it a financial goldmine.
Mr Nigel Lange, former CEO of the bombed-out biotech, Sirtex Medical, was recognized as a global leader in the development and delivery of the radiotherapy treatment for liver cancer, known as SIR-Speres Y-90 resin microspheres. Sirtex Medical created a product that was selling 500 million dollars a year for liver cancer patients. Mr Lange was at the company for 5 years and Sirtex was later acquired by CDH Genetech Ltd in a deal valued at approximately AUD 1.9 billion.
Lange has made his millions and has now recycled his personal capital into this biotech stock that will go up by at least 3 281% to 22 cents according to our analysis.
The Thesis
Here's the deal: traditional radiation therapy is a mess, scattering harmful rays across vital organs in a desperate bid to target the tumor. ASX-listed OncoSil Medical flips the script, injecting a potent, sticky radioactive concoction straight into the cancer's pancreas. This means maximum damage where it is needed, with no casualties among the innocent organs nearby… As opposed to traditional radiation therapy that, in the case of pancreatic cancer, does more harm than good.
Their secret weapon? A radioactive isotope, phosphorus-32, transformed into a cancer-killing beta radiation powerhouse, reminiscent of Lange's former breakthrough liver treatments at Sirtex, with the pivot towards tackling pancreatic cancer this time.
The result? Pain was slashed by 70%, survival rates doubled, and a real shot at surgically removing the beast post-shrinkage. We are talking a new lease on life, 10 to 15 years more, thanks to this brilliant innovation.
A No-Brainer
Why, you ask, would Lange, already sitting on a fortune, dive headfirst into OncoSil Medical? Simple. It's déjà vu with a twist. The same genius that propelled liver cancer treatment into a new era with Sirtex's beta radiation tech is betting big on OncoSil's mission to conquer pancreatic cancer.
A 32-Fold Potential Increase
So, the million-dollar question: Why would a man who's already hit the jackpot with Sirtex throw his weight (and wallet) behind OncoSil Medical? Because Nigel Lange knows this cancer stock is projected to be up to 22 cents in the next few weeks.
Where To Buy OncoSil Medical Shares (ASX: $OSL)
- Stake: https://hellostake.com/au
- Interactive Brokers: https://www.interactivebrokers.com/en/home.php
- CommSec: https://www.commsec.com.au/
- Nabtrade: https://www.nabtrade.com.au/
- Bell Direct: https://www.belldirect.com.au/smarter/